5th Annual Conference on Drug Discovery and Clinical Development:
Meeting the Challenges of Next Generation R&D – Enhancing Efficiency, Effectiveness and Innovation

* TUTORIALS:
October 23, 2010
HOTEL LE MERIDIAN
No. 28, Sankey Road
Bangalore, India

CONFERENCE:
October 24-26, 2010
HOTEL THE LALIT ASHOK
Bangalore, India

* PLEASE NOTE — SEPARATE VENUES
Tutorials are taking place at
THE HOTEL LE MERIDIAN.
The Conference is taking place at
HOTEL THE LALIT ASHOK.
5th Annual Conference on Drug Discovery and Clinical Development

Tutorials: October 23, 2010
Hotel Le Meridian | Bangalore, India

Tutorial Instructors

John Marx
Lorenz Lifesciences, Germany
TUTORIAL #1

Jayaprakash Nallasamy
Lorenz Lifesciences India
TUTORIAL #1

William Sietsema
University of Cincinnati, USA
TUTORIAL #2 & #7

Elke Sennewald
Kendle International
TUTORIAL #2

Abdullah Hassen
Health Authority, Abu Dhabi
TUTORIAL #3

Arun Mishra
GSK, UK
TUTORIAL #3

Ramanan Dayalan
Clinical Data Operation, Take Solutions Ltd., Chennai
TUTORIAL #4

Ganesh Sankaran
Take Solutions Ltd., Chennai
TUTORIAL #4

Shiva Murthy N
Quartesian C.P. Ltd.
TUTORIAL #5

Srinivas Sidgiddi
Connexio Life Sciences, Bangalore
TUTORIAL #5

Sushrut Bhatt
GSK
TUTORIAL #6

Avinash Babu Bonu
Aris Global
TUTORIAL #6

Bhajish Bharathan
Provenance Research India
TUTORIAL #6

Nagalakshmi Padmanabhan
Consortium Clinical Research
TUTORIAL #6

Nayan Nanavati
Consultant
TUTORIAL #7

Mubarak Naqvi
sanofi-aventis
TUTORIAL #8

Sheila Weir
Newron Pharmaceuticals
TUTORIAL #8

Munaf Ali
Consultant
TUTORIAL #8

PHOTO NOT AVAILABLE

PHOTO NOT AVAILABLE

Tutorial Registration
MORNING: 8:00-9:00 AM  AFTERNOON: 12:00-1:00 PM

Pre-Conference Workshop / Tutorials
MORNING TUTORIALS — 9:00 AM-1:00 PM
#1 Moving from CTD to eCTD — Some Practical Considerations
#2 Adaptive Clinical Trials — Overview of Adaptive Elements in Trial Design and Analysis
#3 Regulatory Perspective of Clinical Trials and Clinical Supplies
#4 CDISC STDM Standards

AFTERNOON TUTORIALS — 2:00 PM-6:00 PM
#5 Biosimilars — Prospects and Challenges in the Development, Licensing, and Commercialization
#6 Current Practices In Pharmacovigilance and Risk Management in Drug Safety Surveillance
#7 Overview of Clinical Development Planning
#8 Advanced Project Management

DIA would like to thank all the instructors for their support and active participation.
Moving from CTD to eCTD: Some Practical Considerations

OVERVIEW
- Introduction to eCTD, CTD to eCTD transition
- Discussion on eCTD structure – modules 1 to 5, folder structure, node attributes, leaf element, regional xml file
- Preparing your first eCTD submission – style sheet, ICH and regional DTDs, MD5, checksum, index.xml file
- Preparing your first eCTD submission – submission plan preparation, document preparation, bookmarks, hyperlink, compilation, publishing, validation
- Module 1 differences for US, EU, CA and Switzerland – sample eCTD to US FDA, DMF and ASMF preparation in eCTD with live demonstration
- Study tagging file preparation for clinical/nonclinical studies

Adaptive Clinical Trials: Overview of Adaptive Elements in Trial Design and Analysis

OVERVIEW
- Review of adaptive design trial types – general overview of the types of adaptations that can be considered along with the benefits and disadvantages
- Statistical methods in adaptive trial designs – focus on statistical approaches used in some of the key adaptive trial design options
- Regulatory considerations in adaptive trial designs – what adaptations are considered acceptable to regulatory agencies and how such plans are best shared and negotiated with agencies
- Hands-on workshop – participants to draft their own adaptive designs with consultation and discussion with the course coordinators

Regulatory Perspective of Clinical Trials and Clinical Supplies

OVERVIEW
- Clinical development and clinical trials in emerging markets
- High-level clinical trial regulatory framework in emerging markets
- Clinical trial regulatory path in Canada, US, and Europe

CDISC STDM Standards

OVERVIEW
- Participants will be given CRF and asked to identify SDTM domains and annotate the same
- Trial design domain concepts, SUPPQUAL, RELREC, Dataset, with example
- Participants will be asked to perform an exercise identifying custom domains and their general observation classes

continued on next page
TUTORIAL WORKSHOP #5

Biosimilars: Prospects and Challenges in the Development, Licensing, and Commercialization

OVERVIEW
Participants of this tutorial will learn differences in development of generics and biosimilars, challenges associated with development of biosimilars, advantages of developing biosimilars in India, readiness of CROs to support biosimilars development.

They will also have fair understanding of responsibilities of investigators, patients, physicians, and pharmacists in recommending appropriate use of biosimilars.

Attempts will be made to provide approval processes of biosimilars in India, US, EU regions, and a few interesting case studies relevant to biosimilars development will be discussed.

TUTORIAL WORKSHOP #6

Current Practices in Pharmacovigilance and Drug Risk Management

OVERVIEW
Contextual understanding of pharmacovigilance in the clinical trial setting

- Various clinical trial regulations pertaining to PV
- Case studies

- CIOMS and MedWatch forms
- Causality, seriousness, and expectedness assessments
- Indian regulations, ground realities and the way forward

TUTORIAL WORKSHOP #7

Clinical Development Planning

OVERVIEW
In this tutorial, participants will receive a comprehensive overview of the process used by major pharmaceutical companies for mapping out a clinical development program.

Topics will include some basic phase 1, 2, and 3 study designs, selection of controls, and pediatric and geriatric studies.

- Overview of clinical development planning
- Phase 1 trial designs
- Phase 2 and 3 trial designs
- Selection of controls
- Special population studies – pediatric and geriatric
- Organ impairment studies

TUTORIAL WORKSHOP #8

Advanced Project Management

OVERVIEW
This tutorial will provide the participants with a detailed conceptual knowledge of project management in clinical drug development. The tutorial will cover the concepts of project management as they are applicable in clinical drug development, the project manager’s role in the drug development cycle from early clinical development through phase 2 and 3 clinical research and eventual registration.

- Developing a robust clinical development plan
- Role and importance of the project manager in end-to-end clinical development
- Planning and execution of early clinical development

- Transition from bench to bedside: best practices for incorporating translational research
- Where to conduct phase 1 studies – managing costs and timelines
- Regulatory aspects specific to early clinical development
- The project manager’s role in planning and execution of phase 2 and 3 studies
- Quality management through the entire clinical development
- Putting together the product dossier for submission to health authorities
5th Annual Conference on Drug Discovery and Clinical Development:

Conference: October 24-26
Hotel The Lalit Ashok | Bangalore, India

PROGRAM COMMITTEE
Mubarak Naqvi
Director, Clinical Research, Sanofi-Aventis, India
Suresh Bowalekar
Managing Director, Pharmanet, India
Nandini Kumar
Former Deputy Director General Senior Grade
Moin Don
Associate Director, Johnson & Johnson, India
Albinus D’Sa
Deputy Country Director, USFDA, India
Munish Mehra
Managing Director, Global Drug Development Experts, USA
Nigel McBean
Vice President & Director Operations, IndiPharm, India
Nandkumar Chodankar
Group CEO, Pharma Business Excel Industries, India

ORGANIZING COMMITTEE
Bindhya Cariappa
Director Operations, ClinTec, India
Babu Nema
Head, Pharma Innovation, TCS, India
Ramesh Jagannathan
Associate Director, AstraZeneca, India
Katta Ramanjaneya
Managing Director, SMO-India
Chandrashekhar S.
Director, Bigtec Labs, India
Jayanti Gupta
VP, Clinical Development Semler Research Center, India
Gurudatta GG
Chief Operating Officer, Semler Research Center, India
Sowmyanarayanan Srinivasan
Consulting Manager-Discovery Informatics, Cognizant, India

**Tutorials on October 23, 2010, will take place at Le Meridien Hotel, Bangalore, India.

KEYNOTE SPEAKERS

Lakshmi Narayanan
Vice Chairman, Cognizant
Purvish Parikh
Managing Director, Americares India

SPECIAL GUEST

Bharatesh Jagashetty
Drug Controller, Karnataka India

Hasit Joshipur
Vice President-South Asia, GlaxoSmithKline
Abhijai Barwe
Chief Operating Officer, Clingene International, Ltd.

Rama Mukherjee
Managing Director, ARA Health
Rajiv Ranjan
Executive Vice President & Global Head - Business Operations, Patni Computer Systems

DIA (India) Private Limited
A 303, Wellington Business Park I
Marol Andheri-Kurla Road
Andheri (East), Mumbai - 400059
About Drug Information Association (DIA)

DIA is a professional association of approximately 18,000 members worldwide who are involved in the discovery, development, regulation, surveillance, or marketing of pharmaceuticals or related products. DIA is committed to the broad dissemination of information of new medicines or generics or biosimilars with continuously improved professional practice as a goal.
DAY 1 | SATURDAY, OCTOBER 23

4.00PM - 6.00 PM  CONFERENCE REGISTRATION
Hotel Lalit Ashok, Bangalore, India

8.00 AM - 10.00 AM  TUTORIAL WORKSHOP REGISTRATION
Le Meridien, Bangalore, India

09.00 AM - 01.00 PM  TUTORIAL WORKSHOPS #1 TO #4

#1 Moving from CTD to eCTD
Some Practical Considerations
John Marx
Jayprakash Nallasamy
Lorenz Germany

#2 Adaptive Clinical Trial
Overview of Adaptive Elements in Trial Design and Analysis
William Sietsema
University of Cincinnati, USA
Elke Sennewald
Kendle International

#3 Regulatory Perspective of Clinical Trials and Clinical Supplies
Abdullah Hassen
Health Authority, Abu Dhabi
Arun Mishra
GSK, UK

#4 CDISC STDM Standards
Ganesh Sankaran
Take Solutions
Ramanand Dayalan
Take Solutions

01.00 PM - 2.00 PM  LUNCH BREAK

02.00 PM - 6.00 PM  TUTORIAL WORKSHOPS #5 TO #8

#5 Biosimilars
Prospects and Challenges in the Development Licensing and Commercialization
Shiva Murthy N
Quartesian CR P. Ltd.
Srinivas Sidigiddi
Connexios Life Sciences

#6 Current Practices In Pharmacovigilance and Drug Risk Management
Nagalakshmi Padmanabhan
Consortium Clinical Research Pvt. Ltd.
Sushrut Bhatt
GSK
Bhajish Bharathan
Provenance Research India
Avinash Bonu
Aris Global

#7 Clinical Development Planning
William Sietsema
University of Cincinnati, USA
Nayan Nanavati
Consultant

#8 Advanced Project Management
Mubarak Naqvi
Sanofi Aventis
Sheila Weir
Newron Pharmaceuticals
Munaf Ali
Consultant

DAY 2 | SUNDAY, OCTOBER 24

7.30 AM - 11.00 AM  CONFERENCE REGISTRATION

9.00 AM - 10.30 AM  OPENING CEREMONY
Keynote Speaker
Lakshmi Narayanan
Vice Chairman, Cognizant

10.30 AM - 11.00 AM  REFRESHMENT BREAK/ EXHIBITORS VISITS

11.00 AM - 1.00 PM  SESSION I
CxO Conclave — India, the Emerging Pharmaceutical Powerhouse
The global Pharmaceutical Industry is at an inflection point today. While the core objective of the industry still remains safe & effective treatments, greater access to affordable healthcare and superior product quality including increasing costs of drug discovery & regulatory environment that is still maturing in many parts of world. Leaders from Industry at this DIA CxO Conclave would be focussing on India as a preferred destination for services as well as large untapped market for global pharmaceutical organizations.
A brief presentation of Key Speakers will be followed by a panel discussion.
MODERATOR
Gauri Kamath
Senior Editor, Business World
Panel
Hasit Joshipura
VP, GSK
Shailesh Ayyangar
MD, Sanofi Aventis
Abhijit Barwe
COO Clingene
Deepak Khosla
President SAARC, Patni Computer Systems
Sri Mosur
CEO, President & MD Jubilant Biosys, India
Rama Mukherjee
Managing Director, ARA Health
Manni Kantipudi
President GVK - Bio
2.00-5.30 PM  SESSION II
Innovation or Stagnation - Integrating Innovation in the Corporate culture of Drug Discovery and Development

Starting 2004, the FDA issues several documents indicating "the reasons for the widening gap between scientific discoveries that have unlocked the potential to prevent and cure some of today’s biggest killers, such as diabetes, cancer, and Alzheimer’s, and their translation into innovative medical treatments." Innovation in all aspects of drug discovery and development is critical to overcome the high failure rate, long development times and increasing costs to bring new medical treatments to patients. This session will bring speakers who will share what has been done and what more needs to be done.

MUNIR MEHRA
Global Drug Development

4.00 PM-4.30 PM  REFRESHMENT BREAK/ EXHIBITOR VISIT

DAY 3 | MONDAY, OCTOBER 25
CONCURRENT SESSIONS

09.00AM-10.30 AM  SESSION III  (GRAND BALLROOM)
Metrics and Benchmarking: Why They are Important in Today’s Clinical Operations Organisation

The Pharmaceutical/Biotechnology Industry over last 5-10 years has been heavily focused on implementing efficient and effectiveness processes to improve all aspect of their drug development process. The clinical trial process has been one area, with the formation of a non-profit organisation Metrics Champion Consortium to develop global standard performance metrics for implementation by major pharmaceutical and service providers to improve clinical trial performance in the future. Additionally patient enrolment is key factor and majority of the big Pharma/biotech companies are implementing strategies that help plan, forecast and manage their patient enrolment targets in cost effective manner.

MODERATOR:
Suresh Ramu
Quintiles, India

Global Initiative: Standardisation of Benchmarking in the Clinical Trial Process
Nicole Lee,
PAG ICON Clinical Singapore

Measuring Productivity in CRO Clinical Operations
Nicole Lee,
PAG ICON Clinical Singapore

Balasubramanyan Sankaranarayanan
Cognizant, India

09.00AM-10.30 AM  SESSION IV  (CONVENTION HALL)
Pharmacovigilance and Drug Safety

MODERATOR:
Nilima Kshirsagar
ESI-PGIMSR MGM Hospital

Proactive Risk Management, Challenges and Collaborative Efforts with Pharma Companies - A Regulator’s Perspective
Bhaswat Chakraborty
Cadila Pharmaceuticals, India

The Art of Proactive Pharmacovigilance - An Industry Perspective
Sadhana Joglekar
GSK, India

Drug Safety / Pharmacovigilance KPO - Its Potential, the Future and Anticipated Challenges
Mir Imran Ali
Quintiles, India

10.30-11.00  REFRESHMENT BREAK
Regulatory Challenges: Domestic vs Global

Regulation of drug development is a challenging area when harmonization with global standards would be ideal. Hectic activities are continuing at the office of Drug Controller of India to modernize facilities and resources to meet the challenges of increasing demands on regulation of synthetic drugs besides other forms of formulations that are reaching the Indian market. Monitoring or auditing is being seriously considered by this office. How the industry and the regulators face these challenges would be discussed in this session.

Moderator:

Nandini Kumar
National Institute of Epidemiology

- Clinical Trial Inspections: Current Scenario In India
  A. K. Pradhan
  Deputy DCGI, India
- Overview of Drug Regulatory Requirements and Trends
  Abdullah Hassen
  Health Authority Abu Dhabi
- Regulatory Overview - USFDA India Office
  Albinus D’Sa
  USFDA

Biosimilars

This session will focus on the different stages of ‘development’ of biosimilars in terms of regulatory framework, marketing authorization and their presence in the EU, US and Indian market. It will also provide overview on the product specific guidelines and the latest news concerning the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) and the Patient Protection and Affordable Care Act (PPAC Act), signed into law this year.

Moderator:

Larisa nagra Singh
Voisin Consulting Life Sciences

- Status of Biosimilars in EU and Potential New Development
  Emmanuelle Voisin
  Voisin Consulting Life Sciences
- Biosimilars - An US Perspective
  Subir Basak
  Celestial Biologicals
- Quality Challenges of Biosimilars
  Sanjay Shetgar
  Dr. Reddy’s Laboratories
- Estelle Michael
  GlaxoSmithKline

GOING FOR BRIC: Evolving Sponsor Strategies and Tactics to Access Emerging Markets and Japan Before or After US and EU Registration

The pharmaceutical world has turned its attention to emerging Markets eg: BRIC (Brazil, Russia, India, and China) Because if this current and anticipated high growth rates compared to American and European Markets. Historically, companies have pursued & obtained registration in the US and EU before their attention to Japanese registration. This session will focus on how several companies are approaching Japan and other emerging markets to accelerate drug development and registration in these commercially attractive regions.

Moderator:

Alberto Grignolo
PAREXEL Consulting US

- Experiences in Emerging Markets and Japan: Impact on Global Development
  Joseph Scheeren
  Bayer Healthcare Pharmaceuticals Inc. US
- Evolving Sponsor Strategies and Tactics to Access Emerging Markets
  Arun Mishra
  GSK, UK
- Emerging Markets: The Small to Mid-Sized Company Perspective
  David Mantus
  Cubist Pharmaceuticals, USA

Medical Writing

In the globalised scenario, accessible, credible peer reviewed publications add value to clinical practice, contribute to scientific progress, and have the potential to exert tremendous influence. Therefore, medical writing which interpret scientific information and disseminates the results of clinical trials fundamentals to evidence-based medicine needs to be applied as an art targeting specific requirements. Outsourcing and in-sourcing of medical writing have different requirements for resources for optimal results. In this sessions various aspect of this area will be discussed from academic and industry point of view.

Moderator:

Vis Niranjan
RxMD

- Strategies Facilitating Acceptance of a Research Paper: from Submission to Final Decision
  Sandeep Bavadekar
  TN Medical College & BYL Nair Hospital
- Publication Planning: Effectively Using Publications as a Component of the Overall Strategy
  Sujata Shah
  Sanofi Aventis
- Health Writing for the Public: Ensuring Effectiveness
  Natasha Das
  Consultant
### DAY 4 | TUESDAY, OCTOBER 26

#### CONCURRENT SESSIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XI (GRAND BALLROOM)</th>
<th>Session XII (CONVENTION CENTRE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00 AM-10.30 AM</td>
<td><strong>Biologics and Vaccine Development</strong>&lt;br&gt; This session will cover key developmental aspects related to Vaccines &amp; Biologicals. The recent developments in Regulatory &amp; operational environment will be presented. &lt;br&gt;&lt;br&gt; <strong>Moderator:</strong> Kathy Heard&lt;br&gt; Sanofi Pasteur</td>
<td><strong>Biostatistics</strong>&lt;br&gt; The Clinical trials have been increasingly becoming more complex, newer types of drugs are getting discovered and developed. Establishing efficacy and safety has become a challenge to stakeholders of drug development professionals and regulatory bodies, more so for statistical fraternity. Further, there is growing emphasis on cutting down the duration of trial, using fewer patients and making clinical trial process more efficient. In this session, experts from statistical field will try to share their experiences on topics of current interest. &lt;br&gt;&lt;br&gt; <strong>Moderator:</strong> Suresh Bowalekar&lt;br&gt; Pharmanet, India</td>
</tr>
<tr>
<td></td>
<td>Critical Success Factors in Managing Global Clinical Trials on Vaccines&lt;br&gt; Kathy Heard&lt;br&gt; Sanofi Pasteur</td>
<td><strong>Adaptive Designs - Regulator’s Viewpoint</strong>&lt;br&gt; William Sietsema&lt;br&gt; University of Cincinnati, USA</td>
</tr>
<tr>
<td></td>
<td>Specifications of Biological Products&lt;br&gt; Gautam Maitra&lt;br&gt; AC Immune SA</td>
<td><strong>Guidance Documents for Industry and Science Needs</strong>&lt;br&gt; Ram Tiwari&lt;br&gt; Office of Biostatistics FDA</td>
</tr>
<tr>
<td></td>
<td>The Malaria Vaccine Development Program</td>
<td><strong>Statistical Consideration in Discovery and Evaluation of Biomarkers for Clinical Use</strong>&lt;br&gt; Viswanath Devanarayan&lt;br&gt; Exploratory Statistics, Abbott Laboratories</td>
</tr>
</tbody>
</table>

10.30-11.00 AM  **REFRESHMENT BREAK/ EXHIBITOR VISIT**
**11.00 AM-12.30 PM SESSION XIII (GRAND BALLROOM)**

**Clinical Trial Supplies / Logistics Management — Challenges and Issues of Clinical Trial Logistics from Global and Indian Perspective**

India is now increasing becoming one of the major centres within the global clinical trial market with its involvement set to increase sharply in next 3-5 years. The country undoubtedly offers great advantages in terms of cost, patient pools and clinical expertise – but to take advantage of what India’s has to offer, you require clinical trial logistics (clinical Supply chain, central testing lab, etc.) that are fully adapted to the unique challenges posed in operating in India.

**Moderator:**

**Brigitte Franke-Bray**
DIA European Office

- **Recent Trends in Central Laboratory Services**
  Palat K Menon
  Quest Diagnostics India Pvt. Ltd.

- **Clinical Trials Supplies Emerging Trends and Opportunities**
  Sean Smith
  Thermo Fisher Scientific

- **Cold Chain Management**
  Vinod Jonathan
  World Courier India Pvt. Ltd.

**12.30-1.30 PM LUNCH BREAK**

**1.30-3.30 PM SESSION XV (GRAND BALLROOM)**

**Global Clinical Development and Best Regulator Meeting Practices in the US, EU, Japan, and India**

This session will illustrate best practices in industry-regulator communications with regards to global and local clinical development plans and clinical trials. Examples to relate to the US, EU, Japan, and Indian experiences.

**Moderator:**

**Alberto Grignolo**
PAREXEL Consulting US

- **How to Conduct Effective Clinical Development Meetings with USFDA**
  David Mantus
  Cubist Pharmaceuticals, USA

- **The EU Scientific Advice Process: Roadmap for Clinical Development Success**
  Joseph Scheeren
  Bayer Healthcare Pharmaceuticals

- **DCGI Perspective and Advice on Effective Clinical Trial Consultations with Industry**
  V G Somani - Invited
  Effective Interactions Between Industry and the DCGI Office on Clinical Development
  Mamta Sharma
  PAREXEL Consulting US

**3.30-4.00 PM REFRESHMENT BREAK**

**3.00-5.00 PM**

**Career Development in Clinical Research**

- **Career Development in Pharma and IT Healthcare**
  Archana Jain
  Accenture

- **Vinod Kumar C**
  Aris Global

- **Subbaraju Sagi**
  TechSol

- **Hufriz Karkaria**
  Quintiles

**4.00 PM-5.00 PM**

**Valedictory Function**

- **Larisa Nagra Singh**
  Voisin Consulting Life Sciences

- **Sultan Ghani**
  DIA India

Announcement of the 6th Annual DIA Meeting – Theme, Time, Date, and Location

**5:00 PM CONFERENCE ADJOURNED**

**WATCH FOR THE 2011 DIA CALENDAR OF CONFERENCES!**
TRAVEL AND HOTEL
The Lalit Ashok is located in plush Kumara Krupa High Grounds, overlooking an 18-hole golf course, with key government offices and commercial centers in close proximity. The newly renovated hotel now has a contemporary and elegant look featuring the very latest in design trends, guest amenities, and services. Besides its fabulous location, the hotel is very well known for its creative dining options and extensive banquet facilities. The hotel is about 35 km away from the new International Airport and 5 km from City Center.

For reservations contact: Hotel Lalit Ashok, Bangalore
Contact Person: Mr. Kabir Ahmed
Tel No: 080-30527777 Fax: +91.9845019341
Email: kahmed@thelalit.com

MEETING CONTACTS
Manoj Trivedi, Senior Consultant Marketing & Program Development, DIA (India) Private Limited; Cell: +91.9819777493, fax +91 28594762, Email: Manoj.Trivedi@dia-india.org
Fahd Khan, Manager Marketing & Program Development, DIA (India) Private Limited; Cell: +91-9223267327, Fax: +91-22-28594762, Email: Fahd.Khan@dia-india.org
Pallavi Gokhale, Marketing Assistant, DIA (India) Private Limited; Cell: +91-9819138650, Fax: +91-22-28594762, Email: Pallavi.Gokhale@dia-india.org

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

PLEASE CONSIDER THIS FORM AN INVOICE

5th Annual Conference on Drug Discovery and Clinical Development
Meeting the Challenges of Next Generation R&D: Enhancing Efficiency, Effectiveness & Innovation
Meeting I.D. # 10659 – October 23-26, 2010 – Hotel The Lalit Ashok, Bangalore, INDIA

MEETING CONTACTS
Manoj Trivedi, Senior Consultant Marketing & Program Development, DIA (India) Private Limited; Cell: +91.9819777493, fax +91 28594762, Email: Manoj.Trivedi@dia-india.org
Fahd Khan, Manager Marketing & Program Development, DIA (India) Private Limited; Cell: +91-9223267327, Fax: +91-22-28594762, Email: Fahd.Khan@dia-india.org
Pallavi Gokhale, Marketing Assistant, DIA (India) Private Limited; Cell: +91-9819138650, Fax: +91-22-28594762, Email: Pallavi.Gokhale@dia-india.org

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

REGISTRATION FEES
Registration fee includes refreshment breaks and luncheons and will be accepted by mail or fax.

Join DIA now to qualify to save on future events and to receive all the benefits of membership.
To see all the benefits of DIA membership, visit www.diahome.org and click on Membership.

<table>
<thead>
<tr>
<th>MEMBER</th>
<th>NONMEMBER (Inclusive of Membership)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BASIC RATE</td>
<td>TAXES</td>
</tr>
<tr>
<td>Industry</td>
<td>9418</td>
</tr>
<tr>
<td>Academy</td>
<td>4709</td>
</tr>
<tr>
<td>Student*</td>
<td>2825</td>
</tr>
<tr>
<td>TUTORIALS</td>
<td>Industry, Academia, and Students</td>
</tr>
<tr>
<td>BASIC RATE</td>
<td>TAXES</td>
</tr>
<tr>
<td>Tutorial 1</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 2</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 3</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 4</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 5</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 6</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 7</td>
<td>2825</td>
</tr>
<tr>
<td>Tutorial 8</td>
<td>2825</td>
</tr>
</tbody>
</table>

*A limited number of student registrations are available.
A student is an undergraduate/graduate who can document enrollment in a Signature accredited, degree granting, academic program. Student registration is by fax or mail only. Please send completed registration form, copy of student identification, and payment.

Mail or fax this form to +91-22-28594762.

PAYMENT INFORMATION

.mail to secure
demand draft/cheque

Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to:
DIA (India) Private Limited, A-303, Wellington Business Park I
Andheri-Kurla Road, Marol, Andheri (East), Mumbai 400 059 India
Phone: +91-22-6765-3226 Fax: +91-22-28594762

IF FAXING OR MAILING THIS FORM, PLEASE PROVIDE A COPY OF YOUR BUSINESS CARD.